newsfilter
← Latest News
GlobeNewswire·

Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates

Following U.S. regulatory discussions, accelerated approval strategy remains intact, supported by DENALI Part 2Enrollment completed in Part 2a and 2b of the DENALI trial; Part 2c is enrollingDENALI Part 2 topline